Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR and siRNA manipulation of SOX17 in human pulmonary artery endothelial cells HPAEC

ABSTRACT: CRISPR and siRNA manipulation of SOX17 in human pulmonary artery endothelial cells HPAEC

PROVIDER: PRJNA886991 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21799400_1.fastq.gz	Fastqsanger.gz
	SRR21799400_2.fastq.gz	Fastqsanger.gz
	SRR21799500_1.fastq.gz	Fastqsanger.gz
	SRR21799500_2.fastq.gz	Fastqsanger.gz
	SRR21799401_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 324

Similar Datasets

CRISPR and siRNA manipulation of SOX17 in human pulmonary artery endothelial cells HPAEC

Project description:HPAEC were treated with either siRNA to SOX17 or CRISPR activating or inhibiting the promoter or an enhancer region associated with pulmonary hypertension and sequenced.

2023-07-10 | GSE214742 | GEO

human pulmonary artery (endothelial and smoorh muscle) cells : control vs ARSB-siRNA transfected

Project description:Transcriptional profiling of human pulmonary artery endothelial (HAPEC) and smooth muscle (PASM) cells comparing control untreated cells with cells transfected with ARSB-siRNA. Goal was to determine the effects of silenced of arylsufatase B on global gene expression in HAPEC and PASM cells.

2018-10-01 | GSE115268 | GEO

E2F1 mediates SOX17 Deficiency-Induced Pulmonary Hypertension

Project description:SRY-Box Transcription Factor 17 (SOX17) enhancers variants and mutations are found in patients with pulmonary arterial hypertension (PAH). In human PAH pulmonary microvascular endothelial cells (HPMVEC), there is a significant downregulation of SOX17 expression. We hypothesized that SOX17 deficiency contributes to the pathogenesis of PAH and found that mice with endothelial specific disruption (ecKO Sox17) developed spontaneous pulmonary hypertension (PH) and exacerbated hypoxia-induced PH. Loss of SOX17 in lung ECs induces cell cycle programming, proliferative and anti-apoptotic phenotypes, a process mediated by the activation of E2F Transcription Factor 1 (E2F1) signaling. Pharmacological inhibition of E2F1 in ecKO Sox17 mice attenuated PH and cell cycle programming. Our study demonstrated that endothelial SOX17 deficiency induces PH and targeting E2F1 signaling represents a promising approach in PAH patients.

2023-03-15 | GSE192649 | GEO

Apelin/APJ targeted microRNAs in pulmonary artery endothelial cells

Project description:Evaluation of microRNAs that are downstream of apelin/APJ signaling in the pulmonary artery endothelial cells. Triplicates per group, subjected to: 1) control siRNA, 2) apelin siRNA, 3) APJ siRNA, 4) apelin + APJ siRNA

2012-12-04 | E-GEOD-42343 | biostudies-arrayexpress

Pulmonary artery banded rat heart

Project description:Changes in juvenile rat heart with pulmonary artery banding

2022-05-20 | PXD027427 | Pride

Effects of BMPR2 Loss in Human Pulmonary Artery Endothelial Cells

Project description:Pulmonary arterial hypertension (PAH) is a fatal disease characterized by a proliferative endothelial cell phenotype, inflammation and pulmonary vascular remodeling. BMPR2 loss-of-function has been linked to pathologic plexiform lesions with obliteration of distal pulmonary arteries distal pulmonary arteries BMPR2 silencing inprimary human pulmonary artery ECs (HPAECs) recapitulate important aspects of cellular dysfunction and deregulated signaling associated with PAH. Primary HPAECs were transfected with gene-specific siRNA pools targeting BMPR2 or control siRNA followed PMA or control stimulation.

2015-12-04 | E-GEOD-70456 | biostudies-arrayexpress

E2F1 mediates SOX17 Deficiency-Induced Pulmonary Hypertension [scRNA-seq]

Project description:SRY-Box Transcription Factor 17 (SOX17) enhancers variants and mutations are found in patients with pulmonary arterial hypertension (PAH). In human PAH pulmonary endothelial cells, there is a significant downregulation of SOX17 expression. We hypothesized that SOX17 deficiency contributes to the pathogenesis of PAH and found that mice with endothelial specific disruption (ecKO Sox17) developed spontaneous pulmonary hypertension (PH) and exacerbated hypoxia-induced PH. Loss of SOX17 in lung ECs induced endothelial dysfunctions including upregulation of cell cycle programming and paracrine effect, proliferative and anti-apoptotic phenotypes, impaired cellular junction and BMP signaling. E2F Transcription Factor 1 (E2F1) signaling was showed to mediate the SOX17 deficiency-induced EC dysfunction. Pharmacological inhibition of E2F1 in ecKO Sox17 mice attenuated PH and cell cycle programming. Our study demonstrated that endothelial SOX17 deficiency induces PH through E2F1 and targeting E2F1 signaling represents a promising approach in PAH patients.

2023-06-27 | GSE218398 | GEO

human pulmonary artery (endothelial and smoorh muscle) cells : control vs ARSB-siRNA transfected

Project description:human pulmonary artery (endothelial and smoorh muscle) cells : control vs ARSB-siRNA transfected

| PRJNA474432 | ENA

Proteomics of CLIC4 overexpressing human pulmonary artery endothelial cells

Project description:To identify CLIC4 effectors by studying proteins expressiosn altered by CLIC4 overexpression in human pulmonary artery endothelial cells.

2018-10-16 | PXD008714 | Pride

E2F1 mediates SOX17 Deficiency-Induced Pulmonary Hypertension

Project description:E2F1 mediates SOX17 Deficiency-Induced Pulmonary Hypertension

| PRJNA792563 | ENA